Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of autologous CAR-BCMA CAR-T cells in relapsed/refractory multiple myeloma
MOH_2021-09-14_010257Phase 2Not yet recruiting
- Sponsor
- ד"ר הילה מגן
- Start
- Feb 2021
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of autologous CAR-BCMA CAR-T cells in multiple myeloma (MM) (2 arms), sponsored by ד"ר הילה מגן. Primary endpoints: Safety and Efficacy. Planned start Feb 2021; status: not yet recruiting.
02
Drugs
autologous CAR-BCMA CAR-T cells
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on MOH_2021-09-14_010257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-09-14_010257.